Heart Failure System Reduce Readmissions

CardioMEMS provides physicians with daily information on heart function allowing prevention of heart failure decompensation and hospitalization

 

May 30, 2014
CardioMEMS Heart Failure System FDA Approval

The CardioMEMS Heart Failure System is the firstU.S. Food and Drug Administration (FDA)-approved heart failure (HF) monitoring device shown in clinical trials to significantly reduce hospital admissions.

The CardioMEMS system provides physicians with daily information on heart function allowing prevention of heart failure decompensation and hospitalization. It uses a miniaturized, wireless monitoring sensor is implanted in the pulmonary artery (PA) during a minimally invasive procedure and can then directly measure PA pressure. The system allows patients to transmit this information from their homes to their healthcare providers allowing clinicians to adjust medication and pro-actively implement other treatment options to avoid hospitalization and improve the patient’s condition.

The system received FDA approval in May 2014.

CardioMEMS was purchased by St. Jude Medical immediately after the FDA approval was announced. 

For more information: www.cardiomems.com